

CYCLOSPORIN-CONTAINING PHARMACEUTICAL COMPOSITIONS

Patent number: AU607506B
Publication date: 1991-03-07
Inventor: KURIHARA KOZO; MURANO MASARU
Applicant: SANKYO CO
Classification:
- international: **A61K47/40; A61K47/40;** (IPC1-7): A61K47/40;
A61K37/02
- european:
Application number: AU19880017386 19880603
Priority number(s): JP19870140730A 19870604

[Report a data error here](#)

Abstract not available for AU607506B

Data supplied from the **esp@cenet** database - Worldwide

Application Id : 17386 / 88

Serial Number : 607506

Relevant Act	Patents Act 1990(Transitional)		
Date Application Keyed	15/06/88		
Status : Patent Sealed			
Application Type	Convention application		
Filing Date	03/06/88	Complete Filing Date	03/06/88
Country of origin	JAPAN		
Number of pages	18		
Number of CDROMS			
CDROM Presence			
Filing fee	215		
Earliest Priority Date	04/06/87	Australian OPI Date	22/12/88

Patentee Name
Novartis AG
Address : Lichtstrasse 35,
CH-4002 Basel,
Switzerland

Inventor Name
Kozo Kurihara
Masaru Murano

Invention Title
Cyclosporin-containing pharmaceutical compositions

Full Title
Cyclosporin-containing pharmaceutical compositions

ATTORNEY ADDRESS
Griffith Hack
GPO Box 4164
SYDNEY NSW 2001

EXAMINATION DETAILS

Direction Date	20/07/89	Request Lodgement date	18/09/89
Request Type	Full examination following direction		
Request Fee Paid	260	Acceptance Postponed	
Deferment Date		First Report Date	21/06/90
Examiner J HANSON		Examination Section	S4
Date Sent to Exam	10/12/90	Further Report Date	
Search Results Requested		Search Results Received	
Abstract Requested		Abstract Received	
Re-exam request date			
International (Type) Search Results			

ACCEPTANCE DETAILS

Date Accepted	11/12/90	Acceptance Advert Date	07/03/91
Date FE Printed	08/02/91		
Acceptance Type	After full exam.	Opposition Date	
Applicant Ref 13093-BT:AMP/LT		Opposition Result	
Amend to Spec 2,3			
Amend to ApIn 1			
Amend to Drwg			
Final date for Acceptance	21/03/92		

Application Id : 17386 / 88 607506 status Serial Number : 607506

Date Sealed 23/07/91 Sealed Advertised Date 08/08/91
Accept Not Sealed Advert
Lapsed Advertised Date
Lapsed Type
Withdrawn Advertised Date
Withdrawn Type
Refused Advertised Date Ceased/Expired Advert

CHANGE OF PATENTEE DETAILS:

Assignment under S 187, Reg 19.1 : RECORD 1
Date of Request 31/01/01

Instrument Date(s): 03/08/99 Date of Registration 07/02/01

Instrument Details: Deed of Assignment Date Parties Notified 12/02/01

Enclosures Deed of Assignment
Interest Full
Scope Australia
Service Address Davies Collison Cave
Level 15
1 Nicholson Street
MELBOURNE VIC 3000

Old Name and Address:
Sankyo Company Limited
5-1 Nihonbashi
Honcho 3-chome Chuo-ku
Tokyo
Japan

New Name and Address:
Novartis AG
Lichtstrasse 35,
CH-4002 Basel,
Switzerland

FEE HISTORY

Paid Date	Paid to Date	Fee Paid	Payor Code	Reference
	03/06/90			INITIAL PERIOD
30/05/90	03/06/91	75	CP	
23/04/91	03/06/92	100	CP	
18/05/92	03/06/93	135	CP	
17/05/93	03/06/94	165	CP	
16/05/94	03/06/95	200	CP	
16/05/95	03/06/96	235	CP	
13/05/96	03/06/97	270	CP	
12/05/97	03/06/98	305	CJ	
18/05/98	03/06/99	345	CJ	
17/05/99	03/06/00	385	CJ	
15/05/00	03/06/01	430	CJ	
24/05/01	03/06/02	475	CJ	
29/04/02	03/06/03	525	NV	
14/05/03	03/06/04	650	NV	
12/05/04	03/06/05	700	NV	
10/05/05	03/06/06	800	NV	

PAEN02BE V3.51 PATENT ADMINISTRATION SYSTEM 14/03/06 11:18:16 Page 3

Application Id : 17386 / 88

Serial Number : 607506

607506 status

Last Agency Address
NOVARTIS AG
Patent and Trademark Dept
Klybeckstrasse 141
CH-4002 Basel
SWITZERLAND

PRIORITY DETAILS

Date	Application Number	Country
04/06/87	62-140730	JAPAN

IPC Mark	First
A61K 47/40 (2006.01)	Y
A61K 37/02 (1985.01)	

***** End of Application *****

AU-A-17386/88

<p>89-047015/07 SANKYO KK 04.06.87-JP:140730 (22.12.88) A61k-37/02 A61k-47 Compan. confg. cyclosporin and alpha-cyclodextrin - useful for suppressing the immune system, topical treatment of ocular symptoms of Behcet's syndrome etc. C99-020644</p>	<p>805 SANY 04.06.87 *AU 8817-386-A</p>
<p>Pharmaceutical compsn. comprises at least one cyclosporin (I) together with an amt. of α-cyclodextrin (aCD) or functional deriv. sufficient to solubilise (I) in water.</p> <p>USE</p> <p>For suppressing the immune system, for topical treatment of the ocular symptoms of Behcet's Syndrome, for treatment of herpetic keratitis and spring catarrh, and during kerato- plasty (I) also have antifungal and antiphlogistic activities.</p> <p>ADVANTAGE</p> <p>The water-soluble complex shows reduced tendency for (I) to separate out on contact with water, prevention of in-leak- age, and gives high bioavailability by oral admin. The complex can be formulated into an. compsn. showing reduced ocular irritation and systemic side effects on topical admin. to the eye.</p>	<p>8;2-C, 4-C2B1, 12-A2C, 12-D2B, 12-D7, 12-D8, 12-L4, 12-M2F</p> <p>MORE SPECIFICALLY</p> <p>(I) is cyclosporin A or a mixt. contg. this. The cyclodextrin is aCD, or its ester, ether, aminoalky- lated deriv., salt with an S-confg. acid, carboxyalkylated deriv., addn. cpd. with a mono- or disaccharide, or a polymer confg. aCD in its main chain or pendant to the main chain, esp. acetylated, maltosylated, methylated or aminoethyl- aCD, or aCD sulphate. The wt. ratio of (I): aCD (or deriv) is 1:0.5-1:1000, esp. 1:1-1:200.</p> <p>The compsn. is pref. in the form of an aq. soln. with a concn. of aCD of 13-130, esp. 20-130 mg/ml and a concn. of (I) of 0.1-2.0, esp. 0.2-1.5 mg/ml.</p> <p>EXAMPLE</p> <p>100mg cyclosporin and 10g aCD were dissolved in 50ml of water. The soln. was stirred at room temp. for 2 hrs. and millipore filtered. The filtrate was freeze-dried to give a lyophilised powder which was completely soluble in water equal to the vol. of filtrate to give a transparent soln. (Zipp 1762DAHdWgNo0/0).</p>
	<p>AU8817386-A</p>